Doubling Expression of the Low Density Lipoprotein Receptor by Truncation of the 3′-Untranslated Region Sequence Ameliorates Type III Hyperlipoproteinemia in Mice Expressing the Human ApoE2 Isoform by Knouff, Christopher et al.
Doubling Expression of the Low Density Lipoprotein Receptor by
Truncation of the 3*-Untranslated Region Sequence Ameliorates
Type III Hyperlipoproteinemia in Mice Expressing the Human
ApoE2 Isoform*
Received for publication, October 16, 2000, and in revised form, November 13, 2000
Published, JBC Papers in Press, November 13, 2000, DOI 10.1074/jbc.M009423200
Christopher Knouff‡§, Sudi Malloy‡§, Jennifer Wilder¶, Michael K. Altenburg¶,
and Nobuyo Maeda‡¶i
From the ‡Curriculum in Genetics and Molecular Biology and the ¶Department of Pathology and Laboratory Medicine,
University of North Carolina, Chapel Hill, North Carolina 27599-7525
The primary receptor mediating clearance of apoli-
poprotein (apo)E- and apoB100-containing lipoproteins
from the circulation is the low density lipoprotein (LDL)
receptor. Reduced expression of the LDLR is believed to
be a precipitating factor in the pathogenesis of type III
hyperlipoproteinemia (HLP) in some humans homozy-
gous for the apoE2 allele (APOE*2). To test the effect of
genetic changes in LDL receptor expression on the
pathogenesis of type III HLP, we have generated a var-
iant allele at the endogenous mouse Ldlr locus that ex-
presses the human LDL receptor transcript. Transcrip-
tion of the human LDLR minigene is regulated by the
endogenous mouse promoter sequence, but a truncation
of 3*-untranslated region results in increased mRNA sta-
bility. Consequently, in liver of heterozygotes, steady
state levels of mouse and human LDLR transcripts are
50 and 180% the levels of total transcript in wild type
mice, respectively. Overall, the 2.3-fold normal level of
LDLR message in heterozygotes completely ameliorates
type III HLP caused by the homozygosity for the human
APOE*2 allele, normalizing their plasma lipoprotein
profile. We conclude that a modest increase in expres-
sion of the LDLR through message stabilization is suffi-
cient to prevent precipitation of type III HLP in mice.
Type III hyperlipoproteinemia (type III HLP)1 is a disorder
of lipoprotein metabolism that leads to elevated plasma choles-
terol and triglyceride concentrations due mainly to an increase
of apoB-containing remnant lipoproteins. These particles are
the product of lipolytic processing of chylomicrons and very low
density lipoproteins (VLDL) derived from the intestine and
liver, respectively. Like low density lipoproteins (LDL), these
are atherogenic lipoproteins, and subjects with type III hyper-
lipoproteinemia are predisposed to atherosclerosis and prema-
ture death from myocardial infarction (1).
Type III HLP is a genetic disease associated with the expres-
sion of a metabolically impaired apoE protein (2, 3) or apoE
deficiency (4). It is most commonly associated with individuals
homozygous for the APOE*2 allele, the product of which has
decreased affinity for the LDL receptor compared with other
common isoforms. However, homozygosity of APOE*2 is neces-
sary but not sufficient for the common form of type III hyper-
lipoproteinemia, as only 5–10% of adult homozygotes develop
this disorder. In fact, most APOE*2 homozygotes have mild
hypocholesterolemia and reduced atherosclerosis risk (5).
It has long been appreciated that other genetic and environ-
mental factors besides possession of two APOE*2 alleles are
required for development of type III HLP. Type III HLP rarely
manifests before adulthood, is more prevalent in men than
women, and has an earlier age of onset in men than women (6).
Women tend to express type III hyperlipoproteinemia only
after menopause. Earlier onset is also associated with obesity,
excessive alcohol consumption, diabetes mellitus, and hypothy-
roidism (1). The mechanism by which these conditions induce
type III HLP is unclear. One possibility may be that these
conditions result in down-regulation of hepatic LDL receptor
activity, leading to reduced uptake of atherogenic lipoproteins
containing apoE from plasma. For instance, estrogen has been
shown to increase hepatic LDL receptor activity (7). The de-
crease in plasma estrogen levels in postmenopausal women
would therefore be thought to lead to decreased hepatic LDL
receptor activity and increased circulation time of remnant
lipoproteins.
Previously we have generated mice that express human
apoE2 in a physiologically regulated manner by replacing the
coding sequences of the endogenous mouse Apoe gene with the
human APOE*2 allele (Apoe2/2 mice). These mice exhibit full
penetrance of the type III HLP phenotype, regardless of age or
gender in the presence of normal murine LDL receptor expres-
sion (8). This suggested to us that genetic factors that trigger
the type III HLP phenotype in some humans are already pres-
ent in mice. One possible factor could be a relatively low he-
patic level of the LDL receptor in mice. Others have developed
transgenic mice expressing human apoE2 that exhibit features
of type III HLP when endogenous apoE is absent (9, 10). Un-
regulated overexpression of LDLR gene by adenovirus-medi-
ated gene transfer has been shown to be effective in normaliz-
ing the plasma lipid profiles in these mutants (11). Here we
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report that moderate and controlled overexpression of the LDL
receptor completely ameliorates the type III hyperlipoproteine-
mia phenotype of the Apoe2/2 mice. This increase in LDLR
expression was achieved through enhanced stability of the
LDLR mRNA in mice engineered to express human LDL re-
ceptor in place of the mouse LDL receptor.
EXPERIMENTAL PROCEDURES
Construction of the Human LDLR Replacement Targeting Vector—As
a 59 region of homology, a 7-kb fragment containing intron 1 of the
mouse Ldlr gene was isolated from plasmid pSIT1. Plasmid pSIT1 was
used for a targeted disruption of the murine Ldlr gene by Ishibashi et al.
(12) and was kindly provided by Dr. Shun Ishibashi, University of
Tokyo, Japan. A 12-kb SalI/NotI fragment containing the human LDLR
minigene was isolated from plasmid pMY3, which was used for gener-
ating LDLR transgenic mice by Yokode et al. (13) and was kindly
provided by Dr. Masahiro Yokode, University of Kyoto, Japan. The
human minigene consists of a 7.5-kb fragment of a SalI site in intron 1
through an EcoRI site in exon 5 of the human genomic DNA, a 2.2-kb
fragment of an EcoRI site in exon 5 through a SmaI site in exon 18 of
the human LDLR cDNA (14), and a 0.7-kb fragment of human growth
hormone poly(A) addition signal sequence. As a 39 region of homology,
a 1.4-kb fragment from a SalI site in exon 4 through SacI site in intron
4 of the mouse gene was amplified from mouse genomic DNA by PCR
using primers designed from published cDNA sequence (15). These
fragments were inserted into a TK2 Neo vector to yield the targeting
construct shown in Fig. 1A below. The neomycin phosphotransferase
(Neo) gene was placed in the same transcriptional orientation as the
LDLR gene. The human minigene and the Neo gene replaces ;8 kb of
DNA from an XhoI through a SalI site in exon 4 of the mouse Ldlr gene.
Replacement of the Murine Ldlr Gene with the Truncated Human
LDLR Minigene—The targeting vector was linearized and introduced
into embryonic stem cells, TC-1, and cultured under selection media as
previously described (16). Cells resistant to both G418 and ganciclovir
were clonally isolated and screened by PCR using a Neo-specific primer
59-GCT TCC TCG TGC TTT ACG GT-39 for the targeting construct and
a primer 59-GCA AGA TGG CTC AGC AAG CA-39 corresponding to
intron 4 sequence. Correct targeting was confirmed by Southern blot
analysis using a probe derived from exon 4 of the mouse gene.
Chimeras were generated from targeted ES cells and bred with
C57BL/6 mice to obtain germ line transmission of the modified chro-
mosome. The genotype of the modified allele (h) in the animals was
determined by the presence of a 300-bp PCR fragment produced by
using the Neo-specific primer above and a 39 exon 4-specific primer,
59-GCA GTG CTC CTC ATC TGA C-39. The wild type mouse Ldlr allele
(1) was detected as a 380-bp PCR fragment produced by a 59 exon
4-specific primer 59-CTC CCA GGA TGA CTT CCG AT-39 and the 39
exon 4-specific primer above.
Mice heterozygous for the targeted Ldlr gene (Ldlrh/1) were bred
with Apoe2/2 mice that were homozygous for targeted replacement of the
mouse Apoe gene with the human APOE*2 gene (8). Doubly heterozy-
gous mice were crossed to Apoe2/2 mice again to generate mice homozy-
gous for the human APOE*2 gene and heterozygous for the targeted
Ldlr locus (Apoe2/2 Ldlrh/1 mice). These mice were further crossed to
Apoe2/2 mice to generate littermates homozygous for the human
APOE*2 gene with wild type mouse Ldlr (Apoe2/2 Ldlr1/1 mice) or
homozygous for the human APOE*2 gene and heterozygous for the
human LDLR gene (Apoe2/2 Ldlrh/1 mice) for characterization. All mice
used for characterization were a mix of strains 129 and C57BL6/J and
were fasted for 4 h before plasma lipid analysis. Mice were fed normal
chow (Prolab RMH 3000, number 5P76, St. Louis, MO) or western-style
diet (0.15% (w/w) cholesterol and 21% (w/w) fat, TK 88137, Teklad
Premier, Madison, WI) ad libitum.
Hepatic LDLR mRNA Analysis—Mice were sacrificed with an over-
dose of 2-2-2 tribromoethanol, and livers were harvested, flash frozen in
liquid nitrogen, and stored at 270 °C. RNA was prepared from the
tissue using Trizol reagent following standard protocols (17). For North-
ern blot analysis, a 380-bp fragment of mouse exon 4 and a 350-bp
fragment of human exon 4 were used as probes specific for the mouse
and human genes, respectively. A primer extension assay was designed
to quantitate both human and mouse message simultaneously using a
primer 59-GGA GCA CGT CTT GGG GGG ACA GCC T-39 corresponding
to a shared sequence within exon 3 of the two LDLR genes. Dideoxy-
CTP terminates extension of the primer, resulting in murine message
extension by 5 bp and human message extension by 3 bp. The 30- and
28-bp fragments were separated in a denaturing 20% polyacrylamide
gel. A primer 59-GCA GCG AAC TTT ATT GAT GGT ATT 39 was
included in each reaction to determine the expression of the glyceral-
dehyde-3-phosphate dehydrogenase (Gapdh) gene as an internal con-
trol. Primer extension analysis was performed on 50 mg of total mRNA
as previously described (18). Image densitometry was used to determine
relative amounts of message (FLA-2000, Fuji Photo Film USA Inc.,
Elmsford, NY). To determine the decay rate of the LDLR mRNA,
heterozygous animals were injected via tail vein with actinomycin D
(150 mg/100 g body weight) and a-amanitin (50 mg/100 g body weight).
Animals were sacrificed at various time points after injection, and liver
mRNA was prepared using standard protocols for primer extension
analysis.
Plasma Lipid Analysis—Plasma was isolated and total cholesterol,
HDL cholesterol, and triglycerides were measured as described previ-
ously (19). Equal volumes of plasma from at least five sex- and age-
matched animals were pooled, and lipoproteins were separated by ul-
tracentrifugation or by fast protein liquid chromatography (FPLC) as
described (20). Lipoprotein fractions were dialyzed against phosphate-
buffered saline, pH 7.4, and subjected to SDS-PAGE analysis as
described (20).
In Vivo Clearance of VLDL and LDL—VLDL and LDL fractions were
isolated from plasma of apoE-deficient mice (21) by ultracentrifugation
for use as tracers for the turnover studies. The VLDL and LDL were
radioiodinated with 125I and 131I, respectively, using previously pub-
lished procedures (22, 23). The external jugular vein of recipient mice
was exposed and cannulated with a sterile tapered microrenathane
catheter, and 3 mCi (specific activity ;105 cpm/mg protein) of each
radiolabeled ligand were injected. Immediately after dose injection, the
catheter was removed, and the skin incision was closed using inter-
rupted sutures. Blood samples were collected by retro-orbital sampling
of anesthetized mice at various time points, and radiolabel remaining in
the plasma was quantified with a gamma counter.
RESULTS
Replacement of the Mouse Ldlr Gene with the Truncated
Human LDLR Minigene—The targeting strategy used to dis-
rupt the mouse Ldlr gene and replace it with exons 2–18 of the
truncated human LDLR minigene is illustrated in Fig. 1. Ho-
mologous recombination between the endogenous locus (Fig.
1A) and the targeting construct (Fig. 1B) results in a hybrid
gene in which the human LDLR minigene is expressed under
the control of the endogenous promoter (Fig. 1C). All 59-regu-
latory sequences and exon 1 of the endogenous mouse locus are
intact, but ;8 kb of mouse DNA spanning 39 of intron 1
through exon 4 is replaced with the human LDLR minigene.
The 39-UTR of the minigene is shortened by a deletion of two of
the three 39 “AU-rich elements” that destabilize the mRNA
transcript (24, 25). In addition, the human LDLR minigene
contains the poly(A) addition signal sequences of the human
growth hormone gene. Because exon 1 codes only for the signal
peptide sequence, the mature protein transcribed from the
chimeric gene is entirely human protein. The modified locus
was transmitted to the F1 generation from chimeras that were
made from one of the targeted ES cell lines. All F1 heterozygote
matings produced normal litter sizes with a normal Mendelian
segregation pattern of the modified locus. We designate the
modified allele as hLDLR (or h) to distinguish it from the wild
type mouse Ldlr allele (or 1).
Increased Steady State LDLR mRNA Levels by Enhanced
Message Stability in Heterozygous Mice—The expression of the
LDLR was confirmed by Northern blot analysis of mRNA with
a probe specific for the human LDLR mRNA. The human
message of ;3 kb was present only in animals heterozygous for
the hLDLR (Ldlrh/1) with no band detected in wild type mice
(Ldlr1/1) (Fig. 2A, upper band). The presence of a 4.5-kb mouse
Ldlr message was confirmed in both Ldlr1/1 and Ldlrh/1 mice
by hybridizing the same blot with a probe specific for the mouse
message (Fig. 2A, lower panel). The Ldlrh/1 mice had ;50% of
wild type mouse Ldlr message levels, in accordance with the
loss of one copy of the mouse Ldlr gene.
To estimate simultaneously the amount of both human and
mouse messages in homozygotes, we devised a primer exten-
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sion strategy utilizing a primer that hybridizes to a sequence in
exon 3 shared in both the human and mouse LDLR genes (Fig.
2B). The murine message is extended 5 base pairs, and the
human message is extended 3 base pairs before termination
with dideoxy-CTP. In heterozygotes, the steady state level of
the human LDLR transcript is 3.8 6 0.3 (n 5 18) times the
level of the mouse transcript (p , 0.001). Since the levels of
mouse Ldlr message in the Ldlrh/1 mice are one-half that in
wild type mice, total message (mouse 1 human) is increased
2.3-fold (Fig. 2C). There is no down-regulation of the mouse
message in response to the higher levels of human message,
nor adjustment of total mRNA levels in the Ldlrh/1 mice, de-
spite the fact that transcriptional regulatory elements in the
LDLR gene are intact. The steady state human message is
reduced to 68% of the normal chow level in response to dietary
cholesterol loading (Fig. 2C) indicating that the sterol-respon-
sive transcriptional regulation of the receptor is intact and
functional (26).
To determine if the increased steady state level of the
hLDLR mRNA is due to message stabilization, actinomycin D
and a-amanitin were administered in vivo to Ldlrh/1 mice.
These drugs inhibit transcription, allowing for the measure-
ment of mRNA decay rates (27). Differentiation between the
mouse and human LDLR messages by primer extension was
then used to determine relative decay rates of these transcripts
in the liver (Fig. 3A). The time course analysis (Fig. 3B) shows
that the human message decayed with a half-life of about 160
min while the mouse message decayed with a half-life of 60
min. This confirms that loss of two AREs in the human LDLR
transcript results in a large increase in message stability in
vivo in the liver of mice.
Reduction of Plasma Lipids in Mice Expressing hLDLR—
Both heterozygous (Ldlrh/1) and homozygous (Ldlrh/h) female
mice expressing the hLDLR exhibited approximately a 4-fold
reduction in steady state plasma cholesterol (mainly HDL cho-
lesterol) when fed normal chow (21 6 3 mg/dl in Ldlrh/1, n 5
10; 28 6 8 mg/dl in Ldlrh/h, n 5 8, compared with 85 6 9 mg/dl
in Ldlr1/1, n 5 12 p , 0.00001). The reduction in plasma
cholesterol due to expression of the stabilized hLDLR tran-
script can be viewed as a dominant trait, as there is little
difference in plasma cholesterol between heterozygotes and
homozygotes for the hLDLR. Consequently, all the remaining
characterization was with heterozygous mice and their wild
type littermates. There was a trend toward reduction of plasma
triglycerides in Ldlrh/1 mice (29 6 6 mg/dl, n 5 10) compared
with wild type mice (35 6 7 mg/dl, n 5 12), but this reduction
was not significant (p 5 0.23). Both agarose gel electrophoresis
(Fig. 4A) and FPLC analysis (Fig. 4B) of plasma showed pat-
FIG. 1. Replacement of the murine Ldlr gene with the human LDLR minigene. A, genomic organization of the mouse Ldlr gene
containing exons 1–18 (black boxes). The three AU-rich elements (ARES) in exon 18 are depicted as white rectangles. An asterisk indicates the
position of the stop codon. B, the targeting construct containing the 59 and 39 arms of mouse homology (thick black lines) interrupted by exons 2–4
of the human LDLR gene followed by the LDLR cDNA starting with exon 5. White boxes indicate exons and thin lines indicate introns of the human
gene. The exon 18 is truncated after the first ARE (white rectangle) and followed by the human growth hormone poly(A) addition signal sequence
(black box). A neomycin-phosphotransferase (Neo) and thymidine kinase gene (TK) was inserted for selection of targeted ES cell colonies. C, the
correctly targeted locus results in a chimeric gene encoding the human LDLR.
FIG. 2. Expression of the LDLR genes. A, upper panel, Northern blot analysis using a probe specific for the human LDLR gene. RNA was
isolated from wild type (1/1) or Ldlrh/1 (h/1) mice as genotyped by PCR analysis. Arrows indicate positions for 28 S and 18 S RNA. Lower panel,
the blot above was stripped and re-hybridized to a probe specific for the mouse Ldlr gene. B, primer extension analysis of hepatic RNA isolated
from wild type mice (1/1) and Ldlrh/1 heterozygotes (h/1). The bands representing the mouse LDLR, the human LDLR, and Gapdh transcripts
are indicated. C, liver RNA was isolated from six female 1/1 mice, six female h/1 mice fed normal chow, and nine h/1 mice fed western style diet.
Primer extension was performed on individual samples distinguishing human and murine transcripts, and each was quantified by densitometry
and values are shown as mean 6 S.E. Mouse message, black box; human message, white box. Both mouse and human LDLR messages are
significantly reduced (* p , 0.001) in mice fed western-style diet compared with those in mice fed normal chow.
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terns consistent with a reduction of plasma lipid and HDL
cholesterol. In the Ldlrh/1 mice, both b- and pre-b-migrating
particles, as well as a-migrating particles, were dramatically
reduced. SDS-PAGE analysis of plasma lipoproteins isolated by
sequential density ultracentrifugation showed that the reduc-
tion in plasma lipid was accompanied by reductions in plasma
apoproteins B, E, and AI (Fig. 4C). Although apoB100 is pres-
ent in IDL-LDL fractions (p 5 1.04–1.06 g/ml) of the wild type
mice, it was virtually absent in the IDL-LDL fractions of the
Ldlrh/1 mice (the protein band corresponding to apoB100 was
slightly degraded in this example). Plasma apoE was also re-
duced in all fractions of plasma from Ldlrh/1 mice, with only a
small amount of apoE remaining in the largest, lowest density
particles (VLDL in fraction p 5 1.006 g/ml).
When fed a diet containing 0.15% (w/w) cholesterol and 21%
(w/w) fat, plasma cholesterol levels in Ldlr1/1 and Ldlrh/1 mice
increased to 128 6 10 and 81 6 6 mg/dl, respectively. This
increase was due mainly to the increase in HDL cholesterol, as
shown by FPLC analysis of plasma from both groups of mice
(Fig. 4D). This suggests that both wild type and heterozygous
mice respond similarly to dietary cholesterol overload.
Increased LDLR Level Ameliorates Type III Hyperlipopro-
teinemia in Apoe2/2 Ldlrh/1 Mice—When a copy of the hLDLR
allele was introduced into the mice expressing human APOE*2
in place of mouse Apoe, these mice (Apoe2/2 Ldlrh/1) exhibited a
2.5-fold increase in steady state total LDL receptor mRNA
levels when compared with Apoe2/2 mice (data not shown). The
ratios between the mouse Ldlr and hLDLR mRNA levels were
similar in Apoe1/1 Ldlrh/1 and Apoe2/2 Ldlrh/1 mice.
The Apoe2/2 Ldlr1/1 mice maintained on normal chow had
type III HLP, with plasma cholesterol levels of 268 6 12 mg/dl
and triglycerides of 157 6 22 mg/dl. In contrast, their Apoe2/2
Ldlrh/1 littermates had normal plasma cholesterol and triglyc-
eride levels of 83 6 4 and 40 6 5 mg/dl, respectively. These
values in the Apoe2/2 Ldlrh/1 mice are similar to those of wild
type mice, suggesting that the 2.5-fold increase in LDLR ex-
pression is sufficient to normalize the plasma lipids of the
FIG. 3. Increased human LDLR mRNA stability. A, a radiograph
of primer extension analysis of liver RNA isolated from individual mice
given a bolus tail vein injection of actinomycin D (150 mg/100 g body
weight) and a-amanitin (50 mg/100 g body weight) at time 0. Mice were
sacrificed at the times post-injection indicated. Each lane represents
the RNA from an individual Ldlrh/1 mouse. B, decay of human and
mouse LDLR mRNA in heterozygotes. mRNA levels for hLDLR (open
circles) and mLDLR (closed circles) are expressed relative to the aver-
age levels of mLDLR at time 0. Mean 6 S.E. from 3 to 6 animals at each
time point except for time 0 (10 animals). Half-life for hLDLR (160 min)
and for mLDLR (60 min) was calculated from the first 2 h of the data.
FIG. 4. Plasma lipid and apolipoprotein distribution in wild
type (1/1) or heterozygote (h/1) mice. A, fasted plasma (1 ml) from
males fed normal chow was electrophoresed in a 1% agarose gel and
stained with Fat Red 7B. The positions of a-, b-, and pre-b-lipoproteins
are indicated. B, pooled plasma (100 ml) from 6 male mice fed normal
chow was analyzed by FPLC on a Superose 6B column. 0.5-ml fractions
were collected, and lipid was measured as mg/fraction. TC, total choles-
terol (open circles); TG, triglycerides (closed circles). The numerical
values represent the total plasma levels in mg/dl 6 S.D. from six
animals. C, pooled plasma (1 ml) from Apoe1/1 Ldlr1/1 (1/1). and
Apoe1/1 Ldlrh/1 (h/1) mice fed normal chow was fractionated by se-
quential density ultracentrifugation, and each fraction was electro-
phoresed in a denaturing 3–20% SDS-PAGE gradient gel and stained
with Coomassie Brilliant Blue. Density fractions are as follows: 1.006,
,1.006 g/ml; 1.02, 1.006–1.02 g/ml; 1.04, 1.02–1.04 g/ml; 1.06, 1.04–
1.06 g/ml; 1.08, 1.06–1.08 g/ml; 1.10, 1.08–1.10 g/ml; and 1.21, 1.10–
1.21 g/ml. D, 100 ml of plasma pooled from at least five male mice fed
western-style diet was analyzed by FPLC on a Superose 6B column.
0.5-ml fractions were collected, and lipid was measured as mg/fraction.
TC, total cholesterol (open circles); TG, triglycerides (closed circles). The
numerical values represent the total plasma levels in mg/dl 6 S.D.
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Apoe2/2 mice. The marked reductions in plasma cholesterol and
triglycerides observed in the Apoe2/2 Ldlrh/1 mice can be ac-
counted for by the reduction in b-VLDL, as shown by agarose
gel electrophoresis of whole plasma (Fig. 5A). The lipid content
of a-migrating HDL particles in Apoe2/2 Ldlrh/1 mice was not
reduced in the presence of the hLDLR allele, which is in dis-
tinct contrast to the marked reduction of HDL in Apoe1/1
Ldlrh/1 mice, which have wild type mouse apoE protein.
FPLC analysis of plasma from the Apoe2/2 Ldlrh/1 mice (Fig.
5B) confirmed that reductions in plasma cholesterol were due
to the reduction of cholesterol in large lipoproteins (in the
VLDL and IDL range). There was no change in HDL choles-
terol compared with Apoe2/2 Ldlr1/1 mice. In addition, VLDL
triglycerides are dramatically reduced in Apoe2/2 Ldlrh/1 mice,
whereas triglycerides in remnant particles (fractions 19–25)
are virtually eliminated. One diagnostic criterion for type III
HLP is a ratio of cholesterol/triglyceride in VLDL larger than
0.3. Although the ratio in Apoe2/2 Ldlr1/1 mice is 0.67, the ratio
in Apoe2/2 Ldlrh/1 mice is 0.2, less than the value required for
the diagnosis of type III HLP in humans.
The amelioration of type III HLP in the mice with modestly
increased LDL receptor levels is further shown by SDS-PAGE
analysis of apoproteins in lipoproteins isolated by ultracentrif-
ugation (Fig. 5C). As previously reported, Apoe2/2 Ldlr1/1 mice
fed normal chow have large amounts of plasma apoB, especially
apoB48, as well as apoE in the VLDL fractions (8). In contrast,
Apoe2/2 Ldlrh/1 mice have markedly reduced apoB and apoE
levels in all the non-HDL lipoprotein classes. One important
difference between mice expressing mouse apoE and mice ex-
pressing human APOE*2 is that the Apoe2/2 Ldlrh/1 mice do not
show any reduction in apoAI (or cholesterol) in the HDL frac-
tions, whereas Apoe1/1 Ldlrh/1 mice have significant reduc-
tions in both.
When challenged by western style diet for 3 weeks, Apoe2/2
Ldlrh/1 mice were still protected from type III HLP. Cholesterol
levels increased in Apoe2/2 Ldlrh/1 mice (172 6 43 mg/dl n 5 5)
but were significantly lower than in Apoe2/2 Ldlr1/1 mice
(546 6 30 mg/dl, n 5 3, p , 0.0001). The triglycerides in Apoe2/2
Ldlrh/1 mice did not increase compared with levels on normal
chow (35 6 3 mg/dl n 5 5), whereas they doubled in the Apoe2/2
Ldlr1/1 mice (310 6 84 mg/dl n 5 3). FPLC analysis of plasma
from Apoe2/2 Ldlrh/1 mice (Fig. 5D) fed a high cholesterol diet
demonstrated the continued protection against type III HLP,
with increased cholesterol predominantly in the HDL fractions.
In contrast, the Apoe2/2 Ldlr1/1 mice had markedly increased
VLDL triglyceride as well as VLDL-LDL cholesterol with little
change in HDL cholesterol (Fig. 5D). Taken together, these
results demonstrate that a modest increase in the expression of
LDL receptor mRNA can ameliorate the type III HLP pheno-
type in mice, making them more resistant to diet-induced
hyperlipidemia.
Increased Clearance of Non-HDL Lipoproteins from Plasma
of Apoe2/2 Ldlrh/1 Mice—To ascertain whether the normalized
plasma lipid and lipoprotein levels in Apoe2/2 Ldlrh/1 mice are
due to an increase in functional LDL receptor activity, the
clearance of radiolabeled VLDL and LDL obtained from mice
deficient in apoE was measured. Fig. 6 shows that at 3 h after
injection, significantly more VLDL and LDL remain in the
plasma of Apoe2/2 Ldlr1/1 mice compared with Apoe2/2 Ldlrh/1
mice. This is consistent with our previous observations that
Apoe2/2 mice are unable to clear VLDL from the plasma com-
pletely 4 h post-injection (8). We conclude that the increased
steady state LDLR mRNA levels in Apoe2/2 Ldlrh/1 mice results
in an increase in functional LDL receptor activity, with an
increased fractional catabolic rate of VLDL, as well as LDL,
and normalization of plasma lipid levels.
DISCUSSION
In marked contrast to humans, in which type III HLP affects
5–10% of APOE*2 homozygotes, all mice homozygous for tar-
geted replacement of human APOE*2 exhibit features of type
FIG. 5. Plasma lipid and apolipoprotein distribution in mice
expressing human apoE2 without (2/2 1/1) and with a human
LDLR allele (2/2 h/1). A, fasted plasma (1 ml) from males fed normal
chow was electrophoresed in a 1% agarose gel and stained with Fat Red
7B. B, pooled plasma (100 ml) from 6 male mice fed normal chow was
analyzed by FPLC on a Superose 6B column. 0.5-ml fractions were
collected, and lipid was measured as mg/fraction. TC, total cholesterol
(open circles); TG, triglycerides (closed circles). The numerical values
represent the total plasma levels in mg/dl 6 S.D. C, pooled plasma (1
ml) from Apoe2/2 Ldlr1/1 (2/2 1/1) and Apoe2/2 Ldlrh/1 (2/2 h/1) mice
fed normal chow was fractionated by sequential density ultracentrifu-
gation. Each fraction was electrophoresed in a denaturing 3–20% SDS-
PAGE gradient gel and stained with Coomassie Brilliant Blue. Density
fractions are as follows: 1.006, ,1.006 g/ml; 1.02, 1.006–1.02 g/ml; 1.04,
1.02–1.04 g/ml; 1.06, 1.04–1.06 g/ml; 1.08, 1.06–1.08 g/ml; 1.10, 1.08–
1.10 g/ml; and 1.21, 1.10–1.21 g/ml. D, 100 ml of plasma pooled from at
least five male mice fed western-style diet was analyzed by FPLC on a
Superose 6B column. 0.5-ml fractions were collected, and lipid was
measured as mg/fraction. TC, total cholesterol (open circles); TG, tri-
glycerides (closed circles). The numerical values represent the total
plasma levels in mg/dl 6 S.D.
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III hyperlipoproteinemia regardless of age or gender (8). In the
current study, we have modestly increased steady state hepatic
LDLR mRNA levels by replacing the endogenous mouse Ldlr
gene with an hLDLR minigene with increased mRNA stability.
The Apoe2/2 Ldlrh/1 mice carrying this allele exhibit a 2.5-fold
increase in total hepatic LDLR message, increased clearance of
VLDL and LDL particles from the plasma, and a normal
plasma lipid phenotype. Not only is this modest increase in
hepatic LDLR mRNA sufficient to ameliorate the type III hy-
perlipoproteinemia, the Apoe2/2 Ldlrh/1 mice are more resistant
to diet-induced hyperlipidemia than Apoe2/2 Ldlr1/1 mice.
Brown and Goldstein (26) have demonstrated a regulatory
pathway that results in the down-regulation of LDLR gene
transcription in response to increased intracellular sterol lev-
els. However, regulation of transcription is only one method by
which steady state levels of mRNA are altered. While the 59
regulatory elements of the human LDLR have been studied in
detail, the significance of 39 regulatory elements in the regula-
tion of cellular LDL receptor activity is only beginning to be
appreciated. A few studies of the LDLR 39-UTR indicate that it
may play a significant role in regulation of LDLR mRNA levels.
Wilson et al. (28) have identified three AU-rich elements
(AREs) at positions 2690, 3257, and 3438 of the human tran-
script (14) based on sequence homology with the nonameric
sequence UUAUUUAUU. This sequence is the minimal ele-
ment contributing to a rapid turnover of several mRNAs such
as those encoding immediate early genes and cytokines (24,
25). By fusing the 39-UTR sequence of the human LDLR to the
coding region of human b-globin gene, Wilson et al. (28) dem-
onstrated that the 39-UTR sequence of the LDLR gene confers
a short constitutive half-life to the otherwise stable b-globin
transcript in cultured cells. They showed that fusion constructs
containing all three AREs have a 10-fold higher mRNA turn-
over rate compared with constructs lacking all three AREs. The
three AREs contributed in an additive fashion to the mRNA
destabilization rate, with constructs containing only the 59-
most ARE having just a 3-fold increase in the mRNA degrada-
tion rate. Since the chimeric transcript produced by Ldlrh/1
mice contains only human sequence up to nucleotide 2804, it
lacks two of the AREs. The lack of these two AREs results in a
3-fold increase in the stability of the LDLR message in vitro
(28), an increase in stability similar to what is seen in the mice
in vivo in our current study. Thus in Ldlrh/1 mice there was a
3.8-fold higher steady state level of chimeric human message
compared with wild type mouse message. Since both mLDLR
and hLDLR alleles have identical transcriptional regulatory
sequences, the increase in steady state levels of hLDLR mes-
sage over the wild type mLDLR message must be the direct
result of this increase in message stability.
It is important to note that we found neither down-regula-
tion of the mouse gene accompanying the stabilized human
gene nor normalization of the total LDLR mRNA levels in
heterozygotes. Furthermore, the messages for both mLDLR
and hLDLR alleles are reduced in response to increased dietary
cholesterol to similar degrees, maintaining the same steady
state ratio observed in mice fed normal chow. This suggests
that there is no feedback mechanism to adjust the LDLR
mRNA levels through transcriptional regulation when message
stability is increased in vivo.
Transgenic mice overproducing the human LDL receptor
were reported previously by Yokode et al. (13). These authors
used the mouse metallothionein-I promoter sequence to drive
expression of the human minigene in the transgenic mice.
Similar to our Ldlrh/1 mice, the transgenic mice on low fat diet
had markedly reduced levels of plasma cholesterol and HDL
cholesterol as well as apolipoprotein B and E. The most likely
explanation for the low levels of HDL cholesterol in mice with
increased LDL receptor activity is increased receptor-mediated
clearance of HDL particles with apoE. However, whether other
mechanisms such as inhibition of lipoprotein secretion by in-
creased hepatic LDL receptor activity (29) contribute to lower
HDL cholesterol in these mice require further studies. The
transgenic mice generated by Yokode et al. (13) are completely
protected against diet-induced hypercholesterolemia because
of their unregulated overexpression of the LDLR. In contrast,
HDL cholesterol increased in Ldlrh/1 mice in response to in-
creased dietary cholesterol, as in Ldlr1/1 mice. This suggests
the regulation of transcription of the LDLR gene by increased
cellular sterol levels in Ldlrh/1 mice is intact.
Whereas many factors besides decreased LDL receptor ac-
tivity may precipitate type III HLP in human APOE*2 homozy-
gotes (30), it is clear that high hepatic expression of the LDL
receptor is sufficient to overcome this phenotype in mice. Pre-
vious studies that test the effect of LDL receptor overexpres-
sion on type III HLP in mice have used very high levels of
uncontrolled overproduction of the LDL receptor (9, 31). Our
study is the first to show that as little as a 2.5-fold increase in
LDL receptor mRNA results in increased clearance of VLDL
and a 3–4-fold reduction of plasma cholesterol and triglycer-
ides in mice expressing apoE2 fed normal chow. The fact that
most human APOE*2 homozygotes are slightly hypolipidemic,
but all Apoe2/2 Ldlr1/1 mice are hyperlipidemic, suggests a
possibility that the set point of expression of the LDLR may be
higher in humans than in mice. Murine apoE can efficiently
mediate clearance of plasma lipoproteins by LDL receptor-
independent mechanisms2 Thus, a relatively low set point of
LDLR expression may not influence the overall metabolism of
apoE-containing lipoproteins in mice except when mouse apoE
is replaced with human apoE2, which is far less effective in
mediating LDL receptor-dependent uptake of apoE-containing
lipoproteins.
Three-quarters of LDL receptor proteins in Apoe2/2 Ldlrh/1
heterozygotes are of human sequence. Our unpublished studies
using mouse fibroblast cells show that VLDL containing mouse
apoE or human apoE3 or apoE4 isoforms bind to the mouse
LDL receptor equally well, whereas VLDL with apoE2 binds
2 C. Knouff, V. Clavey, and N. Maeda, unpublished observations.
FIG. 6. Plasma VLDL and LDL clearance rates in mice fed
normal chow. VLDL and LDL were isolated from apoE-deficient mice
by ultracentrifugation. VLDL labeled with 125I and LDL labeled with
131I were injected via jugular vein into Apoe2/2 Ldlr1/1 (2/2 1/1) or
Apoe2/2 Ldlrh/1 (2/2 h/1) mice. At 3 h post-injection, mice were bled
retro-orbitally, and the remaining radiolabel in plasma was measured.
Values shown are percentage of injected radiolabel amount remaining
at 3 h in mean 6 S.D.
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with similar affinity but with 50% Bmax compared with VLDL
containing the other apoE isoforms.2 The results were similar
when human cells were used.2 Thus, species differences in the
affinity of apoE for the LDL receptor do not appear to be
playing a significant role. In contrast, Corsini et al. (32) have
shown that human LDL has much lower affinity to mouse
receptor than to human receptor, suggesting significant species
effects are present in the interaction between apoB100 and the
LDL receptor. Although we did not observe any increase of LDL
in either heterozygotes (Fig. 4) or homozygotes (data not
shown), our present study was carried out in Apoe2/2 Ldlrh/1
heterozygotes to reduce the potential complexities induced by
interactions between mouse LDL and the human LDL receptor.
Several studies have shown that cellular LDL receptor ac-
tivity can be regulated by post-transcriptional mechanisms,
including changes in mRNA stability as well as altered protein
stability. For example, treatment of HepG2 cells with phorbol-
12-myristate-13-acetate has been shown to increase the stabil-
ity of LDLR mRNA 2–2.5-fold by an indirect effect of destabi-
lization of the actin cytoskeleton by this agent (33). Sequences
in the extreme 39-UTR of the LDLR have been shown to confer
association of this RNA with the actin cytoskeleton. Lack of
this region inhibits the PMA-induced stabilization of this RNA
(28). Gemfibrozil, a fibrate drug used in the treatment of type
III hyperlipoproteinemia in humans, also has been shown to
enhance LDLR mRNA stability in human hepatoma cells (34).
In this study pravastatin, an inhibitor of 3-hydroxy-3-methyl-
glutaryl-coenzyme A reductase, significantly increased sterol-
responsive element-dependent transcription (with no effect on
LDLR mRNA stability), whereas gemfibrozil increased LDLR
mRNA stability 4–6-fold with no change in transcription rate.
Whereas both drugs have efficacy in treating type III hyperli-
poproteinemia, pravastatin lowers LDL cholesterol preferen-
tially, and gemfibrozil treatment results in larger reductions in
VLDL cholesterol and triglycerides (35). Whether these differ-
ences are the result of different mechanisms leading to in-
creased LDL receptor activity or are due to other effects of
these drugs on peripheral lipolysis or hepatic VLDL secretion
has not been resolved.
That the regulation of LDLR mRNA stability may have a
physiological role is suggested by the fact that depletion of
hepatic sterol by the inhibition of squalene synthase results in
increased LDLR mRNA transcription, stability, and transla-
tion in rats (36). Whether alterations of LDLR mRNA levels in
humans due to regulated alterations in mRNA stability can be
a “precipitating factor” for type III hyperlipoproteinemia is
unclear. Nevertheless, our present study makes clear that
changes in hepatic LDLR levels due solely to differences on
LDLR mRNA stability can have a profound effect on plasma
lipid levels in a mouse model of type III HLP.
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